NEW HAVEN, Conn., March 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company, announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical ...
NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics announced today that it has been awarded a $3.3 million grant from the National Institutes of Health as part of its Small ...
Allyx Therapeutics, a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases, announced that the ...
NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company which is developing ALX-001, a highly selective, first-in-class, synapse-targeted, ...
(MENAFN- GlobeNewsWire - Nasdaq) Allyx's lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in neurodegenerative diseases NEW HAVEN ...
(MENAFN- GlobeNewsWire - Nasdaq) Allyx continues to advance clinical research of its first-in-class oral compound for neurodegenerative diseases NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ...
Funding will support metabolism studies of ALX-001, a first-in-class oral therapy in clinical development for Alzheimer's disease and Parkinson's disease NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results